Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: An 8-week, double-blind, randomized study on magnitude and timing of clinical response

Psychological Medicine

Volumn 41, Issue 10, 2011, Pages 2089-2097

  Wade, A G ^a   Crawford, G M ^a   Nemeroff, C B ^b   Schatzberg, A F ^c   Schlaepfer, T ^d,e   McConnachie, A ^f   Haazen, L ^g   Buntinx, E ^g  

^a CPS Research   (United Kingdom)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF BONN   (Germany)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g PharmaNeuroBoost NV ^*  (Belgium)

Author keywords

Citalopram; depression; Montgomery Asberg Depression Rating Scale; pipamperone; selective serotonin reuptake inhibitors

Indexed keywords

BUTYROPHENONE DERIVATIVE; CITALOPRAM; PIPAMPERONE; PLACEBO; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; STANDARD; TREATMENT OUTCOME; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; BUTYROPHENONES; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SCOTLAND; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80054881008     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291711000158     Document Type: Article

References (28)

1. Anderson IM (2003). Drug treatment of depression: reflections on the evidence. Advances in Psychiatric Treatment 9, 11-20. (Pubitemid 36114008)
2. APA (2000). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. American Psychiatric Association: Washington, DC.
3. Artigas F (2001). Limitations to enhancing the speed of onset of antidepressants-are rapid action antidepressants possible? Human Psychopharmacology 16, 29-36. (Pubitemid 32218878)
4. Blier P, Szabo ST (2005). Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. Journal of Clinical Psychiatry 66, 30-40. (Pubitemid 43004173)
5. Buntinx E, Peremans K, Schlaepfer T, Audenaert K, De Spiegeleer B, Megens A (2008). Preclinical and clinical evidence for the efficacy of pipamperone in augmenting the antidepressant effects of the SSRI citalopram. International Journal of Neuropsychopharmacology 11, 190.
6. Celada P, Puig M, Amargos-Bosch M, Adell A, Artigas F (2004). The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. Journal of Psychiatry and Neuroscience 29, 252-265. (Pubitemid 39185866)
7. Demyttenaere K, Enzlin P, Dewe W, Boulanger B, De Bie J, De Troyer W, Mesters P (2001). Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. Journal of Clinical Psychiatry 62 (Suppl. 22), 30-33. (Pubitemid 32937583)
8. Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Balasubramani GK, McGrath PJ, Thase ME, Klinkman M, Nierenberg AA, Yates WR, Fava M (2008). Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. Journal of General Internal Medicine 23, 551-560.
9. Gillespie CR, Garlow SJ, Schatzberg AF, Nemeroff CB (2009). Biology of mood disorders. In Textbook of Psychopharmacology (ed. A. F. Schatzberg and C. B. Nemeroff), pp. 903-944. American Psychiatric Publishing Inc.: Washington, DC.
10. Guy W (1976). Clinical global impressions. In ECDEU Assessment Manual for Psychopharmacology (ed. W. Guy), pp. 217-222. US Department of Health, Education, and Welfare: Washington, DC.
11. Hamilton M (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 23, 56-62.
12. Kato M, Fukuda T, Wakeno M, Okugawa G, Takekita Y, Watanabe S, Yamashita M, Hosoi Y, Azuma J, Kinoshita T, Serretti A (2009). Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 150B, 115-123.
13. Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, Keller MB (2009). A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. Journal of Psychiatric Research 43, 205-214.
14. Keller MB, Hirschfeld RM, Demyttenaere K, Baldwin DS (2002). Optimizing outcomes in depression: focus on antidepressant compliance. International Clinical Psychopharmacology 17, 265-271. (Pubitemid 35283713)
15. Kinney GG, Taber MT, Gribkoff VK (2000). The augmentation hypothesis for improvement of antidepressant therapy: is pindolol a suitable candidate for testing the ability of 5HT1A receptor antagonists to enhance SSRI efficacy and onset latency? Molecular Neurobiology 21, 137-152. (Pubitemid 32434067)
16. Landen M, Thase ME (2006). A model to explain the therapeutic effects of serotonin reuptake inhibitors: the role of 5-HT2 receptors. Psychopharmacology Bulletin 39, 147-166.
17. Machado-Vieira R, Salvadore G, Luckenbaugh DA, Manji HK, Zarate Jr CA (2008). Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. Journal of Clinical Psychiatry 69, 946-958. (Pubitemid 351944948)
18. Masand PS (2003). Tolerability and adherence issues in antidepressant therapy. Clinical Therapeutics 25, 2289-2304. (Pubitemid 37076320)
19. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382-389. (Pubitemid 9136500)
20. Moulin-Sallanon M, Charnay Y, Ginovart N, Perret P, Lanfumey L, Hamon M, Hen R, Fagret D, Ibáñez V, Millet P (2009). Acute and chronic effects of citalopram on 5-HT1A receptor-labeling by [18F]MPPF and-coupling to receptors-G proteins. Synapse 63, 106-116.
21. Murray CJ, Lopez AD (1997). Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349, 1498-1504. (Pubitemid 27216360)
22. Peremans K, De Spiegeleer B, Buntinx E, Dobbeleir A, Vermeire S, Vandermeulen E, De Vos F, Megens A, Eersels J, Audenaert K (2008). Evaluation of serotonin-2A receptor occupancy with 123I-5-I-R91150 and single-photon emission tomography before and after low-dose pipamperone administration in the canine brain. Nuclear Medicine Communications 29, 724-729.
23. Stassen H, Angst J, Delini-Stula A (1998). Onset of improvement under fluoxetine and moclobemide. European Psychiatry 13, 128-133. (Pubitemid 28261346)
24. Svensson TH, Mathe AA (2002). Monoaminergic transmitter systems. In Biological Psychiatry (ed. H. A. H. D'Haenen, J. A. den Boer and P. Willner), pp. 45-66. John Wiley & Sons: Chichester, UK.
25. Thase ME, Entsuah AR, Rudolph RL (2001). Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. British Journal of Psychiatry 178, 234-241. (Pubitemid 32183606)
26. Wade A, Friis Andersen H (2006). The onset of effect for escitalopram and its relevance for the clinical management of depression. Current Medical Research and Opinion 22, 2101-2110. (Pubitemid 44789974)
27. Watson JM, Dawson LA (2007). Characterization of the potent 5-HT1A/B receptor antagonist and serotonin reuptake inhibitor SB-649915: preclinical evidence for hastened onset of antidepressant/anxiolytic efficacy. CNS Drug Reviews 13, 206-223. (Pubitemid 47052350)
28. WHO(2008). The Global Burden of Disease: 2004 Update. World Health Organization: Geneva, Switzerland http://www.who.int/healthinfo/global-burden- disease/2004-report-update). Accessed 29 November 2010.